<DOC>
	<DOCNO>NCT00193622</DOCNO>
	<brief_summary>This trial investigate combination bevacizumab , erlotinib patient adenocarcinoma poorly differentiate carcinoma unknown primary site . Bevacizumab erlotinib relatively well-tolerated non-overlapping toxicity profile . This trial one first clinical trial evaluate combination target agent treatment solid tumor .</brief_summary>
	<brief_title>Bevacizumab Erlotinib Treatment Patients With Carcinoma Unknown Primary Site</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Bevacizumab + Erlotinib</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>To include study , must meet following criterion : Carcinoma unknown primary site confirm biopsy Measurable disease ECOG performance status must 01 Adequate bone marrow , liver kidney Understand nature study give write informed consent . You participate study follow apply : Age &lt; 18 year May receive EGFR inhibitor History acute myocardial infarction within 6 month Clinically significant cardiovascular disease Moderate severe peripheral vascular disease . History stroke within 6 month History abdominal fistula , perforation , abscess within 6 month Active concurrent infection Serious underlie medical condition Active brain metastasis Women pregnant lactating . PEG Gtube Proteinuria Any nonhealing wound , ulcer , bone fracture . Any clinical evidence history bleeding , clot coagulopathy Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>